Clinical trials: SARS CoV 2 Virus
SARS-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04487574
- Testing
- XC221
- Where
- 5 sites in Russia
- Volunteers
- 118 people
- Sponsor
- RSV Therapeutics LLC
COVID-19
Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy population aged 3 to…
- Trial name
- NCT05003479
- Testing
- SARS-CoV-2 Vaccine (Vero Cells), Inactivated
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangtai Biological Products Co., LTD
COVID-19
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
This is a phase 1 study to assess the safety and immunogenicity of different formulations of the investigational adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine (SCB-2020S vaccine), when…
- Trial name
- NCT05228314
- Testing
- Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based adjuvant
- Where
- 3 sites in South Africa
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
SARS-CoV-2
Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients
A descriptive, clinical series, single-centre, national, biomedical study to determine the presence of SARS-CoV-2 in sperm samples from positive PCR patients for COVID-19 and to evaluate the presence of the virus in the sperm…
- Trial name
- COVID-19CAST (NCT04717011)
- Testing
- PCR test
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Igenomix
COVID-19, SARS-CoV-2 Infection
Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers
Double blind, Multi-Centre study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of…
- Trial name
- BBV152 (NCT04471519)
- Testing
- BBV152A - Phase I, BBV152B - Phase I, BBV152C - Phase I
- Where
- 12 sites in India
- Volunteers
- 755 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Healthy Volunteers
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers
The goal of this clinical trial was to learn about the safety and tolerability of an investigational drug called Benfo-oxythiamine (B-OT) in healthy male volunteers.
- Trial name
- BOOST (NCT07450833)
- Testing
- Benfo-oxythiamine
- Where
- Bulgaria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Benfovir AG
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
COVID-19
Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years
This was a non-randomized, three-armed, open-label, parallel-group, non-inferiority trial designed to compare the immunogenicity and safety of the SpikoGen COVID-19 vaccine in children aged 5 to <12 years and 12 to <18 years with…
- Trial name
- NCT05231590
- Testing
- Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Cinnagen
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.
- Trial name
- COVID-19 DTH (NCT05216510)
- Testing
- TNX-2110, TNX-2120, TNX-2130
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
COVID-19
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine
This trial is observer-blind, comparative, randomized, placebo-controlled phase 2 study. The population is healthy subjects aged 18 and above
- Trial name
- NCT05313035
- Testing
- SARS-CoV-2 protein subunit recombinant vaccine
- Where
- 3 sites in Indonesia
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Thrombopenia, Covid19
COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients
This is a multicenter, open-label, single cohort study of patients with confirmed COVID-19 syndrome who based on clinical judgment require care in an intensive care unit, regardless of whether or not mechanical ventilation is in…
- Trial name
- NCT05040776
- Testing
- EP-7041 Injection
- Where
- United States
- Sponsor
- eXIthera Pharmaceuticals
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
- Trial name
- NCT05677893
- Testing
- MBS-COV
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
COVID-19, SARS-CoV-2
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of coronavirus disease 2019 (COVID-19).
- Trial name
- AZD2816 (NCT04973449)
- Testing
- AZD1222, AZD2816
- Where
- 35 sites in Brazil, Poland and 2 more
- Volunteers
- 2,843 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
SARS-CoV-2 Infection (Asymptomatic), SARS-CoV-2 Infection (Symptomatic)
COVID-19 Progression in End-Stage Kidney Disease
The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
- Trial name
- COPE (NCT04495907)
- Where
- 11 sites in United States
- Volunteers
- 412 people
- Sponsor
- Davita Clinical Research
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077332
- Testing
- Famotidine, Celecoxib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
SARS-CoV-2 Infection
Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
Recently published studies could demonstrate that detection of specific biomarkers in breath could be applied for the diagnosis of SARS-CoV-2.
- Trial name
- NCT04547114
- Testing
- Multicapillary column coupled ion mobility spectrometry
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Klinikum Bayreuth GmbH
COVID
Niclosamide In Moderate COVID-19
This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.
- Trial name
- NCT04436458
- Testing
- Niclosamide Oral Tablet
- Sponsor
- Entero Therapeutics
COVID-19 Pneumonia, COVID-19 Respiratory Infection
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05212532
- Testing
- EOM613
- Where
- 4 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- EOM Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.